FibroGen, Inc.

As of August 8, 2025, FibroGen, Inc. shows a bullish technical trend overall, supported by positive weekly momentum indicators, but caution is advised due to mixed signals from daily moving averages and underperformance against the S&P 500.

As of March 2, 2020, FibroGen, Inc. is considered overvalued and risky due to negative valuation ratios and underperformance compared to peers and the S&P 500.

As of March 2, 2020, FibroGen, Inc. is considered overvalued and in financial distress, with a negative P/E ratio and poor valuation metrics compared to peers, despite a recent stock performance increase of 1929.31%.

As of June 18, 2025, FibroGen, Inc. has shifted to a bullish trend with moderate strength, supported by a bullish MACD and moving average, though caution is advised due to bearish RSI readings.

As of March 2022, the management team of FibroGen, Inc. includes Chairman James Schoeneck, CEO Enrique Conterno, Lead Independent Director Thomas Kearns, and Directors Aoife Brennan, Benjamin Cravatt, Suzanne Blaug, and Jeffrey Edwards. They oversee the company's strategic direction and operations.

FibroGen, Inc. is a biopharmaceutical company focused on developing first-in-class therapeutics. As of March 2025, it reported net sales of $3 million and a net loss of $17 million, with a market cap of $23.77 million.

As of Jun 18, FibroGen, Inc. has a market capitalization of 23.77 million, with net sales of 102.85 million and a net profit of -58.05 million over the last four quarters. Shareholder's funds are -225.60 million, and total assets are 214.53 million.